Showing 9 RESULTS FOR
Parkinson's disease
Lundbeck in the News: Spotlight on Parkinson’s Sidekicks™ Program
News coverage of unique Lundbeck-Davis Phinney program that unites people with Parkinson’s disease and youth for art and storysharing projects.
Report Offers Hope, Outlines 537 New Drugs in Development for Neurological Disorders
A new report shows there are 537 medicines in development for neurological disorders, such as Parkinson's disease and Alzheimer's disease. Learn how Lundbeck is advancing treatments for brain disorders.
Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care Partners
Results from a nationwide survey highlighting patient and care partner perception of the impact and burden of neurogenic orthostatic hypotension (nOH) and its symptoms point to the need for heightened education and awareness of nOH.
Lundbeck Brings Potential New Biologic Treatment of Parkinson’s Disease into Clinical Development
H. Lundbeck A/S (Lundbeck) begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the first participant in a Phase I study with the compound Lu AF82422.
Lundbeck Starts Clinical Development of Potential New Treatment of Parkinson's Disease
H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a potential new treatment of Parkinson’s disease. The compound – Lu AF28996– is invented by Lundbeck and will now be studied in healthy volunteers as first part of its clinical development.